CRE
Pseudomonas
ESBL
Limited treatment options
Bacteraemia
Treatment with ZAVICEFTA suggested a trend towards lower all-cause 30-day mortality compared with colistin36*
ZAVICEFTA demonstrated promising clinical results for severe infections caused by OXA-48-producing Enterobacterales for which treatment options are limited38*
Consultant Microbiologist from Guy’s and St. Thomas’ NHS Trust talks about the benefit of new antibiotics to treat CRE. He also presents his experience using ZAVICEFTA in a patient in intensive care with MDR Klebsiella.
In the largest real-world study¶ with specific data on patients treated with ZAVICEFTA for P. aeruginosa infections, the composite clinical failure** and development of resistance was similar between the CRE and P. aeruginosa cohorts:4,49*
In a real-world retrospective multicentre study†† of patients who received ≥72 h of ZAVICEFTA for Gram-negative bacteria other than CRE, the clinical cure‡‡ rate was high across different causative agents:6*
Treatment with ZAVICEFTA suggested a trend towards lower 30-day mortality compared with other treatment41*
Treatment with ZAVICEFTA suggested a trend towards lower all-cause 30-day mortality compared with colistin36*
Treatment with ZAVICEFTA suggested a trend towards lower all-cause 30-day mortality compared with colistin36*
Treatment with ZAVICEFTA suggested a trend towards lower all-cause 30-day mortality compared with colistin36*
Treatment with ZAVICEFTA suggested a trend towards lower all-cause 30-day mortality compared with colistin36*
Pfizer AS, Org.nr 915 213 596
Postadresse: Postboks 3, 1324 Lysaker
Besøksadresse: Drammensveien 288, 0283 Oslo
Tlf.: +47 67 52 61 00
PP-BCP-NOR-0001 juni 2023
Copyright © 2023 Pfizer AS. Innholdet er rettighetsbeskyttet.
Dette nettstedet er kun for helsepersonell.
Jeg bekrefter at jeg er helsepersonell som definert i legemiddelforskriften §13-1.
Ved å velge "nei" vil du komme til Pfizer.no som er åpen for allmenheten.